«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:

期数:

2017年02期

页码:

147-149

栏目:

论著

出版日期:

2017-03-27

文章信息/Info

Title:

Comparison of clinical effect of S-1 combined Paclitaxel and FOLFOX regimen in the treatment of advanced gastric cancer

作者:

陈巧; 崔同建; 刘振华; 陈静波

福建医科大学省立临床医学院福建省立医院肿瘤内科，福州350001

Author(s):

CHEN Qiao;  CUI Tong-jian;  LIU Zhen-hua;  CHEN Jing-bo

Department of Oncology, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, China Corresponding author：CHEN Qiao, E-mail: 13321192663@163.com

关键词:

晚期胃癌; 替吉奥; 紫杉醇

Keywords:

Advanced gastric cancer;  S-1;  Paclitaxel

分类号:

R735.2

DOI:

-

摘要:

目的比较替吉奥联合紫杉醇方案与传统FOLFOX 方案（奥沙利铂+氟尿嘧啶+亚叶酸钙） 治疗晚期胃 癌的疗效和安全性。方法选取福建医科大学省立临床医学院福建省立医院62 例晚期胃癌患者，随机分为观 察组34 例和对照组28 例。观察组行替吉奥联合紫杉醇方案化疗，对照组行FOLFOX 方案（奥沙利铂+氟尿嘧 啶+亚叶酸钙） 化疗，化疗期间定期监测血常规、肝肾功能，2 个周期后进行疗效评价，即病灶最大径总和变化。 结果观察组有效率55.88%，疾病控制率为91.18%，均优于对照组，两组比较差异均无统计学意义(χ2=0.21、 1.97，P>0.05）。两组不良反应为轻度的骨髓抑制、消化道反应等，均可耐受。结论替吉奥联合紫杉醇和传 统FOLFOX 方案两组治疗方案均可用于晚期胃癌，疗效相当，不良反应发生症状轻，患者可耐受。

Abstract:

Objective To compare the efficacy and safety of S-1 combined with paclitaxel and traditional FOLFOX scheme (oxaliplatin + fluorouracil + leucovorin) in treatment of patients with advanced gastric cancer. Methods Sixty-two patients with advanced gastric cancer, who came from Fujian provincial hospital, were randomly divided into the observation group (n=34) and the control group (n=28). The observation group received S-1 combined with paclitaxel, and the control group received FOLFOX regimen (oxaliplatin+fluorouracil +leucovorin). The blood routine，liver and kidney function were regularly monitored during chemotherapy. The curative effect which was the change of the maximum diameter was evaluated after 2 cycles of chemotherapy. Results The effective percentage of the observation group was 55.88% , and the disease control rate was 91.18% . The effective percentage of the control group was 50.00%, and the disease control rate was 78.57%. There was no significant difference between the two groups (χ2=0.21 or 1.97, all P>0.05). Adverse reactions in patients in the two gruops were mild bone marrow suppression, gastrointestinal reactions, and so on, and they all can be endured. Conclusion S-1 combined paclitaxel and traditional FOLFOX regimen have the similar effect in the treatment of patients with advanced gastric cancer and had mild and tolerable adverse effect.

参考文献/References:

[1] Fuse N, Fukuda H, Yamada Y, et al. Updated results ofrandomized phase III study of 5- fluorouracil alone versus combination of irinotecan and cisplatin versus S- 1 alone in advanced gastric cancer (JCOG 9912) [J]. Clin Oncol (Meeting Abstracts), 2009,27(15S):4514.
[2] Park I, Lee JL, Ryu MH, et al. Phase I/II and Pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer [J]. Cancer Chemother Pharmacol, 2010, 65(3):473-480.
[3] 曹桂侠,程朝辉,周冬梅.替吉奥联合奥沙利铂治疗晚期胃癌的临 床观[J].肿瘤基础与临床,2011,24(1):27-29.
[4] 周际昌.实用肿瘤内科学[M].北京:人民卫生出版社,2010:29-30.
[5] 张思维,陈万青,郑荣寿,等.2003-2007 年中国癌症死亡分析[J]. 中国肿瘤,2012,21(3):171-178.
[6] 周恒根,倪敬中,刘兰芳,等. 替吉奥胶囊联合紫杉醇治疗晚期胃 癌28例临床观察[J].中国现代药物应用,2011,5(11):3-4.
[7] 杨全良,曾冬香,凌扬,等. 紫杉醇联合替吉奥胶囊治疗晚期胃癌 的临床观察[J].中国肿瘤临床与康复,2011,18(4):359-361.
[8] Huang DZ, Xiong JP, Ba Y, et al. A phase Ⅱ prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma [J]. Chinese J Oncology, 2012, 34(11):865-868.

备注/Memo

备注/Memo:

作者简介：陈巧，硕士，主治医师，研究方向：肿瘤内科 通信作者：陈巧，E-mail: 13321192663@163.com

常用功能

更新日期/Last Update: 2017-02-18